Federal ban on abortion pill creates unlimited liability for manufacturer

What it does

This bill withdraws FDA approval of mifepristone (the abortion pill) for pregnancy termination, making it illegal to manufacture or distribute for that purpose. It also creates a federal civil lawsuit right allowing any woman who claims harm from mifepristone to sue the manufacturer for compensatory damages, punitive damages, and attorney's fees, with no cap on liability and no requirement to prove the drug caused the harm beyond the woman's own attribution.

Why we flagged it

The bill's primary mechanism is withdrawal of FDA approval for mifepristone, which restricts access to a previously approved drug. The secondary mechanism—a federal tort with no causation requirement and unlimited damages—is designed to create financial deterrence against the manufacturer and potentially other entities in the supply chain.

What the text implies

• The tort liability is structured with an unusually low causation bar ('attributable, in whole or in part'), meaning a woman need only claim the drug contributed to any bodily injury or mental health harm to establish liability—no requirement to prove the drug was the sole or primary cause.
• Punitive damages are explicitly available, which may expose the manufacturer to liability far exceeding actual compensatory harm and may create incentive for plaintiffs to file claims even where causation is speculative.
• The bill does not limit the scope of 'harm to mental health' (defined to include 'emotional' harm), which is subjective and difficult to defend against in litigation.
• Withdrawal of approval is retroactive to previously approved uses, potentially affecting women who relied on the drug's legal status when they used it.
• The 90-day effective date for the tort creates a window where the drug remains technically available but manufacturers face imminent unlimited liability, likely accelerating market exit.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Women lose access to a medication that was previously approved and available under federal law, eliminating one option for pregnancy termination. The bill does not replace this option with alternatives or support; it simply removes it. The federal tort creates liability without requiring proof of causation (only that harm is 'attributable, in whole or in part' to use), which may chill future pharmaceutical development but does not restore the lost medical option.

Who stands to gain

• Plaintiff's bar (tort litigation)
• State attorneys general (if they pursue enforcement under state law)

Named in the bill

FDA (Food and Drug Administration), Mifepristone (Mifeprex, RU-486), Danco Laboratories (manufacturer), Federal district courts, State courts

Where it stands

7 cosponsors: 7 Republicans.

• Mar 11, 2026 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 11, 2026 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $420,000 in lobbying spend. A filing names 51 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Josh Hawley, the sponsor, reported $68,000 in PAC receipts in the 2026 cycle.

• Susan B Anthony List — $420,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.